Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €7.49 EUR
Change Today -0.03 / -0.40%
Volume 11.9K
TXCL On Other Exchanges
EN Paris
As of 11:35 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

txcell (TXCL) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - €10.65
52 Week Low
05/4/15 - €5.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TXCELL (TXCL)

Related News

No related news articles were found.

txcell (TXCL) Related Businessweek News

No Related Businessweek News Found

txcell (TXCL) Details

TxCell S.A., a biotechnology company, develops T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases. The company’s product candidates include Ovasave, a T cell immunotherapy product, which is in Phase IIb placebo controlled study for refractory Crohn's disease; and Col-Treg for the treatment of rare disease Autoimmune Uveitis. Its products in preclinical development stage comprise Myelin-Treg for central nervous system inflammatory diseases; and HSP60-Treg for autoimmune and inflammatory diseases. The company has a strategic partnership with Trizell Holding SA for the development of Ovasave. TxCell S.A. is headquartered in Valbonne, France.

70 Employees
Last Reported Date: 10/20/15

txcell (TXCL) Top Compensated Officers

Executive Chairman
Total Annual Compensation: €60.0K
Vice President of Supply Chain
Total Annual Compensation: €104.0K
Compensation as of Fiscal Year 2014.

txcell (TXCL) Key Developments

TxCell S.A. Announces Revenue Results for the Third Quarter and Nine Months of 2015

TxCell SA announced revenue results for the third quarter and nine months of 2015. For the third quarter, the company generated revenues of €348,000 compared with €245,000 for the same period in 2014. For the nine months, the company generated revenues of €882,000.

TxCell SA Enters into Exclusive Option Agreement with Yeda Research and Development

TxCell SA announced that it has entered into an exclusive option agreement with Yeda Research and Development Co. Ltd. Resulting from the exclusive option agreement, TxCell will gain exclusive access to a CAR-Treg patent for suppression of autoimmune and inflammatory diseases originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar. The patent application under the option that TxCell has obtained covers redirected, genetically engineered T regulatory cells (CAR-Treg) and their use in suppression of autoimmune and inflammatory diseases. The option agreement grants TxCell until June 30, 2016 to opt-in at predefined terms.

TxCell Seeks Partnerships

TxCell S.A. (ENXTPA:TXCL) will seek contract manufacturing organizations (CMO) partnerships in EU, US and Asia for the GMP manufacturing of its clinical and commercial products. These partnerships will be in addition to existing relationships with MaSTherCell (BE) and Cell Therapy Catapult (UK), both based in Europe. It is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to CMOs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXCL:FP €7.49 EUR -0.03

TXCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXCL.
View Industry Companies

Industry Analysis


Industry Average

Valuation TXCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.9x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TXCELL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at